J. Hardwick

发表

A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.

S. Vowler, Chunsheng Zhang, C. Caldas, 2010, Gastroenterology.

Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers

Chunsheng Zhang, J. Hardwick, V. Save, 2010, Proceedings of the National Academy of Sciences.

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

Angela M. Liu, Yingrui Li, Chunsheng Zhang, 2012, Nature Genetics.

Genome-wide identification of RNA editing in hepatocellular carcinoma.

Huanming Yang, Jun Wang, Yingrui Li, 2015, Genomics.

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Jason G. Jin, M. Ayers, I. Sohn, 2015, Nature Medicine.

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

Rob Pieters, Christopher Winter, Giulio Draetta, 2007, The Journal of experimental medicine.

The Activated Form of the Lck Tyrosine Protein Kinase in Cells Exposed to Hydrogen Peroxide Is Phosphorylated at Both Tyr-394 and Tyr-505*

J. Hardwick, B. Sefton, James S. Hardwick, 1997, The Journal of Biological Chemistry.

Activation of the Lck tyrosine protein kinase by hydrogen peroxide requires the phosphorylation of Tyr-394.

J. Hardwick, B. Sefton, James S. Hardwick, 1995, Proceedings of the National Academy of Sciences of the United States of America.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma

Hancheng Zheng, Xiao Liu, Zhuolin Gong, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

TNER: A Novel Bayesian Background Error Suppression Method for Mutation Detection in Circulating Tumor DNA

Tao Xie, J. Bienkowska, Shibing Deng, 2017, bioRxiv.

Immunohistochemical Detection of Antitumor, Antimetastasis, and Antiangiogenesis Effects of a Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor in an Orthotopic Breast Cancer Metastasis Model

B. Connolly, J. Hardwick, N. Kohl, 2010 .

Activation of the Lck Tyrosine-protein Kinase by the Binding of the Tip Protein of Herpesvirus Saimiri in the Absence of Regulatory Tyrosine Phosphorylation*

J. Hardwick, B. Sefton, D. Hartley, 1999, The Journal of Biological Chemistry.

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

J. Hardwick, D. Chua, F. Roila, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins.

S. Schreiber, F. Kuruvilla, A. Shamji, 1999, Proceedings of the National Academy of Sciences of the United States of America.

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

J. Baselga, J. Tabernero, J. Hardwick, 2011, Clinical Cancer Research.

Cancer Therapy : Clinical A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab ( MK-0646 ) , an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody , in Patients with Advanced Solid Tumors

J. Tabernero, S. Cosimo, J. Hardwick, 2011 .

Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma

Olga K Afanasiev, J. Becker, M. Cleary, 2014, Cancer Immunology Research.

Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein.

S. Schreiber, J. Hardwick, R. Peterson, 1999, Proceedings of the National Academy of Sciences of the United States of America.

N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)

J. Buckner, D. Moore, E. Galanis, 2007 .

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

Xudong Dai, Theresa Zhang, Jing Yuan, 2009, Cancer research.

Development of vorinostat: current applications and future perspectives for cancer therapy.

J. Hardwick, V. Richon, J. Garcia-Vargas, 2009, Cancer letters.

Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.

S. Jagannath, J. Hardwick, G. Schiller, 2012, Clinical lymphoma, myeloma & leukemia.

The transcriptional profile of Saccharomyces cerevisiae exposed to rapamycin mimics the profile induced by amino acid starvation

S. Schreiber, J. Hardwick, J. Tong, 1999, Nature Genetics.

Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

R. Bernards, H. Kerl, R. Dummer, 2012, Leukemia & lymphoma.

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Caterina Giannini, Jan C Buckner, B. Scheithauer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

Lin Li, Shibing Deng, Hongyue Dai, 2013, Genome research.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer

Zhou Zhu, Shibing Deng, P. Rejto, 2019, Oncogene.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, A. Shaw, 2017, JCO precision oncology.

Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling

Robert L. Phillips, Chunsheng Zhang, J. Lamb, 2005, Molecular Cancer Therapeutics.

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study

J. Hardwick, J. Boice, H. Schmoll, 2010, Supportive Care in Cancer.

Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy

P. Rejto, L. Chen, J. Hardwick, 2021, Molecular Imaging and Biology.

Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.

M. Maitland, R. S. Huang, A. Loboda, 2015, Journal of the National Cancer Institute.

Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia

C. Kenific, K. Kunii, J. Hardwick, 2009, British journal of pharmacology.

TNER: a novel background error suppression method for mutation detection in circulating tumor DNA

Tao Xie, Kai Wang, Shibing Deng, 2018, BMC Bioinformatics.

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors

J. Hardwick, T. Otsuki, T. Tamura, 2009, Cancer science.

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

Jason G. Jin, Joon-Oh Park, H. Dai, 2014, Nature Communications.

RESEARCH PAPER Down-regulation of the Notch pathway mediated by a g-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia

P. Majumder, C. Kenific, K. Kunii, 2009 .

TNER: a novel background error suppression method for mutation detection in circulating tumor DNA

J. Bienkowska, Shibing Deng, P. Rejto, 2018, BMC Bioinformatics.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008 .

A potential role for Periostin in Barrett’s carcinogenesis

Chunsheng Zhang, H. Dai, G. Tokiwa, 2007 .

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Paolo Vicini, Deepak Dalvie, Chad Ray, 2016 .

Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Moderately Emetogenic (MEC) Chemotherapy in Patients with Breast Cancer.

J. Hardwick, A. Carides, J. Street, 2009 .

9048 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic (MEC) or highly emetogenic (HEC) chemotherapies in patients with lung cancer

J. Hardwick, J. Boice, R. Gralla, 2009 .

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

Angela M. Liu, Chunsheng Zhang, Yujie Hu, 2012, Nature Genetics.

Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.

A. Look, J. O'neil, J. Hardwick, 2009, Cancer research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors

B. Clurman, R. Sears, R. Pieters, 2007, The Journal of experimental medicine.